62212-22-0

Basic information

• Product Name: bis(4-methoxybenzyl)diselane
• CAS NO: 62212-22-0
• Molecular Formula: C₁₆H₁₈O₂Se₂
• Molecular Weight: 400.2329
• Mol File: 62212-22-0.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 496°C at 760 mmHg
• Flash Point: 253.8°C
• Vapor Pressure: 1.72E-09mmHg at 25°C
• CAS DataBase Reference: bis(4-methoxybenzyl)diselane(CAS DataBase Reference)
• NIST Chemistry Reference: bis(4-methoxybenzyl)diselane(62212-22-0)
• EPA Substance Registry System: bis(4-methoxybenzyl)diselane(62212-22-0)

Safety Data

• Hazardous Substances Data: 62212-22-0(Hazardous Substances Data)

Usage

General Description

Bis(4-methoxybenzyl)diselane is a complex organic compound which is generally used in the field of chemistry, particularly in laboratory settings, as an intermediate in organic synthesis. It comprises of two parts which are made up of 4-methoxybenzyl group, linked by diselane (a molecule with two selenium atoms). It's a colorless, liquid chemical at room temperature. Due to the presence of Selenium, it is necessary to handle bis(4-methoxybenzyl)diselane with care as selenium compounds can be toxic. It is not a naturally occurring chemical, but instead a man-made substance for specific scientific applications.

Upstream product

• 123-11-5 4-methoxy-benzaldehyde 
• 105-13-5 4-Methoxybenzyl alcohol 
• 513-81-5 2,3-dimethyl-buta-1,3-diene 
• 824-94-2 p-methoxybenzyl chloride 
• 13033-52-8 N-(2-propyl)-4-methoxybenzylideneamine 
• 68-12-2 N,N-dimethyl-formamide 
• 72552-08-0 1-methoxy-4-(selenocyanatomethyl)benzene 
• 1416982-07-4 1-(4-methoxyphenyl)-N,N,N-trimethylmethanaminium trifluoromethanesulfonate 
• 15175-54-9 N,N-dimethyl-4-methoxylbenzylamine 

Downstream Products

• 847354-75-0 (4-methoxy-phenyl)-methaneselenol 
• 150308-80-8 N-(9-fluorenylmethoxycarbonyl)-Se-(p-methoxyphenylmethyl)-L-selenocysteine 
• 342904-13-6 Fmoc-(Se)-p-methoxybenzylselenocysteine-OAll 
• 1268809-46-6 prop-2-en-1-yl (2S)-3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-2-({[(4-methoxyphenyl)methyl]selanyl}methyl)propanoate 
• 1268809-47-7 (2S)-3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-2-({[(4-methoxyphenyl)methyl]selanyl}methyl)propanoic acid 
• 1268809-50-2 prop-2-en-1-yl (2S)-3-{[(1,1-dimethylethoxy)carbonyl]amino}-2-({[(4-methoxyphenyl)methyl]selanyl}methyl)propanoate 
• 1268809-52-4 (2S)-3-{[(1,1-dimethylethoxy)carbonyl]amino}-2-({[(4-methoxyphenyl)methyl]selanyl}methyl)propanoic acid 
• 1268809-56-8 H-β2hSec(PMB)-β3hAla-β3hLeu-β3hIle-OH*TFA 
• 1276043-79-8 (Z)-(1,4-diphenylbut-1-en-3-ynyl)(4-methoxylbenzyl)selane 
• 959415-39-5 (R)-2-((tert-butoxycarbonyl)amino)-3-((4-methoxybenzyl)selanyl)propanoic acid 
• 1275614-52-2 C₁₆H₂₃NO₅Se 
• 1275614-39-5 C₁₁H₁₄O₃Se 
• 1275614-44-2 C₁₇H₂₃NO₄Se 
• 1275614-40-8 [(4-methoxybenzyl)selanyl] acetic acid 

Relevant articles and documents

Synthesis of Dibenzylic Diselenides from Elemental Selenium and Benzylic Quaternary Ammonium Salts

Abstract: Substituted dibenzyl diselenides are synthesized in good yields (74–91 %) by SN2 nucleophilic substitution of benzylic trimethylammonium salts and diselenide dianion (Se2?), in situ generated from elemental selenium, under

Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections

A series of selenium-containing miconazole derivatives were identified as potent antifungal drugs in our previous study. Representative compound A03 (MIC = 0.01 μg/mL against C.alb. 5314) proved efficacious in inhibiting the growth of fungal pathogens. However, further study showed lead compound A03 exhibited potential hemolysis, significant cytotoxic effect and unfavorable metabolic stability and was therefore modified to overcome these drawbacks. In this article, the further optimization of selenium-containing miconazole derivatives resulted in the discovery of similarly potent compound B17 (MIC = 0.02 μg/mL against C.alb. 5314), exhibiting a superior pharmacological profile with decreased rate of metabolism, cytotoxic effect and hemolysis. Furthermore, compound B17 showed fungicidal activity against Candida albicans and significant effects on the treatment of resistant Candida albicans infections. Meanwhile, compound B17 not only could reduce the ergosterol biosynthesis pathway by inhibiting CYP51, but also inhibited biofilm formation. More importantly, compound B17 also shows promising in vivo efficacy after intraperitoneal injection and the PK study of compound B17 was evaluated. In addition, molecular docking studies provide a model for the interaction between the compound B17 and the CYP51 protein. Overall, we believe that these selenium-containing miconazole compounds can be further developed for the potential treatment of fungal infections.

Design, synthesis, and biological evaluation of novel miconazole analogues containing selenium as potent antifungal agents

Herein, based on the theory of bioisosterism, a series of novel miconazole analogues containing selenium were designed, synthesized and their inhibitory effects on thirteen strains of pathogenic fungi were evaluated. It is especially encouraging that all the novel target compounds displayed significant antifungal activities against all tested strains. Furthermore, all the target compounds showed excellent inhibitory effects on fluconazole-resistant fungi. Subsequently, preliminary mechanistic studies indicated that the representative compound A03 had a strong inhibitory effect on C.alb. CYP51. Moreover, the target compounds could prevent the formation of fungi biofilms. Further hemolysis test verified that potential compounds had higher safety than miconazole. In addition, molecular docking study provided the interaction modes between the target compounds and C.alb. CYP51. These results strongly suggested that some target compounds are promising as novel antifungal drugs.